Synthetic Lethality in Ovarian Cancer
Open accessAbstract
Ovarian cancers include several distinct malignancies which differ with respect to clinicopathologic features and prognosis. High-grade serous cancer is the most common histologic subtype and accounts for most ovarian cancer–related deaths. High-grade serous ovarian cancer (HGSOC) is treated with surgery and platinum-based chemotherapy, but most patients relapse and succumb to chemoresistant disease. The genetic concept of synthetic lethality, in which the synergy of mutations in multiple genes results in cell death, provides a framework to design novel therapeutic approaches to overcome chemoresistance in ovarian cancer. Recent progress in understanding the genomic architecture and hereditary drivers of ovarian cancer has shown potential for synthetic lethality strategies designed around homologous DNA repair. Clinical trials have validated high response rates for PARP inhibitors in patients with BRCA1 or BRCA2 mutations. Here we discuss the biological rationale behind targeting BRCA–PARP synthetic lethality based on genetic context in ovarian cancer and how this approach is being assessed in the clinic. Applying the concept of synthetic lethality to target non–BRCA-mutant cancers is an ongoing challenge, and we discuss novel approaches to target ovarian cancer using synthetic lethality in combination with and beyond PARP inhibitors. This review will also describe obstacles for synthetic lethality in ovarian cancer and new opportunities to develop potent targeted drugs for patients with ovarian cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Interfering with SSB could destroy HR-deficient cancer cells.
“Based on this synthetic lethality theory, interfering SSB could destroy HR-deficient cancer cells [221].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [221]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 86 · Cited by 41
Research works printed but not linked: 5
- [5]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines®) [Internet]; 2019. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1040842806000643?via%3Dihub.
- [18]Bridges CB. The origin of variations in sexual and sex-limited characters. Am Soc Nat 1922; 56: 51– 63.
- [48]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines®) ovarian cancer including fallopian tube cancer and primary peritoneal cancer [Internet]; 2020. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1040842806000643?via%3Dihub.
- [55]Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019; 1– 13. PMC6941439 31562800
- [58]Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, et al PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer. Cell Rep 2018; 25: 2972– 80. 30540933 PMC6366450
- Authors
- Chandrasekaran, A., & Elias, K. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Elias, Kevin M.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2021-09-13
- Volume
- 20
- Issue
- 11
- Pages
- 2117-2128
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- PMC
- PMC8571039
- OpenAlex
- W3199748251
- Cited by
- 41
- References
- 86
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 10 · 2022: 13
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Cancer Therapeutics (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health & Human Development (K12 HD000849)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Keywords
- synthetic lethality, ovarian cancer, high-grade serous ovarian cancer, PARP inhibitors, BRCA1, BRCA2, homologous recombination repair, chemoresistance, targeted therapy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Synthetic Lethal Mutations, Female, Humans, Ovarian Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
